Latest Safety News

Carbonxt Group Limited has initiated a $2 million Share Purchase Plan following successful capital raises, aiming to bolster its Kentucky activated carbon facility as it nears commercial production.

New Hope Group delivered a robust quarterly performance with a 21.8% rise in underlying EBITDA and a 33% jump in saleable coal production for the first half of FY25, underpinned by operational efficiencies and strategic investments.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.

Aurizon’s half-year FY2025 results reveal a 4% EBITDA decline despite a 6% increase in coal volumes, alongside mixed safety outcomes and an extended $300 million buy-back program.

Aurizon Holdings posted a 3% revenue increase to $2.02 billion for 1HFY2025 but saw EBITDA dip 4% to $814 million, reflecting operational headwinds across key segments. The company declared a 9.2 cents per share interim dividend, signaling cautious optimism despite margin pressures.

BlueScope Steel reported a resilient $309 million underlying EBIT for 1H FY2025 despite depressed steel spreads, announcing a 30 cents per share interim dividend and extending its buy-back program. The company is targeting a $500 million incremental EBIT uplift by 2030 through cost initiatives and strategic growth projects.

BlueScope reported a $179 million net profit for 1H FY2025 amid challenging steel market conditions, while announcing a 30 cents per share dividend and a $240 million buy-back plan. The company is banking on cost initiatives and market recovery to boost earnings in the second half.

BlueScope Steel’s half-year results for December 2024 reveal a sharp 63% decline in underlying NPAT amid lower steel spreads and rising costs, yet the company raises its interim dividend and extends its share buy-back program, signaling confidence in a recovering second half.

Westpac’s 1Q25 update reveals a resilient $1.7 billion net profit and strong loan growth despite margin pressures and economic headwinds.

LGI Limited reports a solid H1 FY25 performance with modest revenue growth and increased EBITDA, driven by expanded biogas flows and carbon abatement activities. The company confirms a positive outlook with a 12-15% underlying EBITDA growth forecast for FY25.

Imugene’s Phase 1b trial of azer-cel, an off-the-shelf CD19 CAR T therapy, reports a 57% complete response rate in heavily pretreated diffuse large B-cell lymphoma patients, signaling a promising new option in a challenging cancer landscape.

Austal Limited has landed a landmark A$270 million contract to design and build a 130-metre hydrogen-ready high-speed ferry for Sweden’s Gotlandsbolaget, marking a major step in sustainable maritime transport.